BOS-172722 is a selective inhibitor of the KRAS G12C mutant protein, primarily investigated for its potential in cancer therapy, particularly targeting solid tumors associated with KRAS mutations. KRAS is a gene commonly mutated in various cancers, and this compound inhibits the function of the abnormal protein resulting from these mutations, thereby disrupting cancer cell proliferation. It is being developed as a targeted therapy, which may help reduce side effects compared to traditional chemotherapy. Researchers are exploring its efficacy in preclinical studies, focusing on its ability to inhibit tumor growth and enhance the effectiveness of existing treatments. Its application is being studied in combination therapies to improve outcomes for patients with resistant or advanced cancers. Ongoing research aims to establish its safety profile and optimal dosing for clinical use. The research remains in experimental stages, with preliminary results indicating promise for a new generation of anti-cancer drugs.